HK92089A - Improvements in or relating to cephalosporin derivatives - Google Patents

Improvements in or relating to cephalosporin derivatives

Info

Publication number
HK92089A
HK92089A HK920/89A HK92089A HK92089A HK 92089 A HK92089 A HK 92089A HK 920/89 A HK920/89 A HK 920/89A HK 92089 A HK92089 A HK 92089A HK 92089 A HK92089 A HK 92089A
Authority
HK
Hong Kong
Prior art keywords
cephalexin
monohydrate
crystalline
solvate
cephalexin hydrochloride
Prior art date
Application number
HK920/89A
Other languages
German (de)
English (en)
Inventor
Gary Lowell Engel
Joseph Michael Indelicato
Harry Albert Rose
Lawrence Joseph Mcshane
Kuo Shang Yang
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HK92089A publication Critical patent/HK92089A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

1. Chlorhydrate de céphalexine cristallin à une molécule d'eau.
2. Formulation pharmaceutique comprenant, comme ingrédient actif, du chlorhydrate de céphalexine cristallin à une molécule d'eau en association avec un ou plusieurs excipients ou supports pharmaceutiquement acceptables pour cette formulation.
3. Chlorhydrate de céphalexine cristallin à une molécule d'eau destiné à être utilisé comme produit pharmaceutique.
4. Procédé de préparation de chlorhydrate de céphalexine cristallin à une molécule d'eau, caractérisé en ce qu'il consiste à hydrater un produit de solvatation d'alcanol en Cl-C4 d'un chlorhydrate cristallin en exposant ce produit de solvatation à une atmosphère ayant une teneur en humidité relative de 10 à 50%.
5. Procédé selon la revendication 4, caractérisé en ce que le produit de solvatation d'un alcanol en C,-C2 d'un chlorhydrate cristallin est hydraté.
6. Procédé selon la revendication 5, caractérisé en ce que le produit de solvatation est le produit de solvatation de l'éthanol.
7. Produit de solvatation d'un alcanol en C1―C4 d'un chlorhydrate de céphalexine cristallin.
8. Produit de solvatation d'éthanol d'un chlorhydrate de céphalexine cristallin.
HK920/89A 1983-12-01 1989-11-16 Improvements in or relating to cephalosporin derivatives HK92089A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/556,887 US4600773A (en) 1983-12-01 1983-12-01 Crystalline cephalexin hydrochloride monohydrate

Publications (1)

Publication Number Publication Date
HK92089A true HK92089A (en) 1989-11-24

Family

ID=24223233

Family Applications (1)

Application Number Title Priority Date Filing Date
HK920/89A HK92089A (en) 1983-12-01 1989-11-16 Improvements in or relating to cephalosporin derivatives

Country Status (46)

Country Link
US (1) US4600773A (fr)
EP (1) EP0143658B1 (fr)
JP (1) JPS60132990A (fr)
KR (1) KR870000527B1 (fr)
AT (1) AT390616B (fr)
AU (1) AU566080B2 (fr)
BE (1) BE901142A (fr)
BG (1) BG40966A3 (fr)
BR (1) BR8406037A (fr)
CH (1) CH661732A5 (fr)
CS (1) CS248725B2 (fr)
CY (1) CY1505A (fr)
DD (1) DD229410A5 (fr)
DE (1) DE3443065A1 (fr)
DK (1) DK158354C (fr)
ES (1) ES538019A0 (fr)
FI (1) FI80274C (fr)
FR (1) FR2555990B1 (fr)
GB (1) GB2150566B (fr)
GR (1) GR81043B (fr)
GT (1) GT198400146A (fr)
HK (1) HK92089A (fr)
HU (1) HU192516B (fr)
IE (1) IE57886B1 (fr)
IL (1) IL73639A (fr)
IN (1) IN163078B (fr)
IT (1) IT1177329B (fr)
JO (1) JO1347B1 (fr)
LU (1) LU85650A1 (fr)
MA (1) MA20279A1 (fr)
MX (1) MX159670A (fr)
MY (1) MY102966A (fr)
NL (1) NL8403588A (fr)
NO (1) NO844711L (fr)
NZ (1) NZ210357A (fr)
OA (1) OA07876A (fr)
PH (1) PH20849A (fr)
PL (1) PL146014B1 (fr)
PT (1) PT79553B (fr)
SE (1) SE464026B (fr)
SG (1) SG59789G (fr)
SU (1) SU1251807A3 (fr)
YU (1) YU45680B (fr)
ZA (1) ZA849224B (fr)
ZM (1) ZM6384A1 (fr)
ZW (1) ZW19084A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2555989B1 (fr) * 1983-12-06 1987-02-20 Bristol Myers Sa Monohydrate de chlorocephadroxyle
JPS60142987A (ja) * 1983-12-29 1985-07-29 Mochida Pharmaceut Co Ltd セフアロスポリン誘導体
DE3485860T2 (de) * 1983-12-29 1993-01-14 Mochida Pharm Co Ltd Cephalosporinverbindungen, verfahren zu ihrer herstellung und pharmazeutishe praeparate.
US4840945A (en) * 1985-04-01 1989-06-20 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
US4775751A (en) * 1985-06-03 1988-10-04 Eli Lilly & Company Process for cephalexin hydrochloride alcoholates
US4880798A (en) * 1986-11-25 1989-11-14 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
JPS63132893A (ja) * 1986-11-25 1988-06-04 Mochida Pharmaceut Co Ltd 新規セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
US5721229A (en) * 1995-12-26 1998-02-24 Veterinary Pharmacy Corporation Soluble forms of cephalosporins and treatment of animals
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
US20040033262A1 (en) * 2002-08-19 2004-02-19 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507861A (en) * 1966-09-14 1970-04-21 Lilly Co Eli Certain 3-methyl-cephalosporin compounds
US3655656A (en) * 1970-06-04 1972-04-11 Lilly Co Eli Crystalline cephalexin monohydrate
DE2317179C2 (de) * 1973-04-05 1982-11-25 Bristol-Myers Co., 10154 New York, N.Y. Verfahren zur Herstellung der relativ wasserunlöslichen kristallinen Form von Cefalexinmonohydrat
US3985747A (en) * 1974-05-24 1976-10-12 Bristol-Myers Company Crystalline sesquihydrate of 7-[D-α-amino-α-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid
JPS50151890A (fr) * 1974-05-30 1975-12-06
CH642850A5 (it) * 1978-10-20 1984-05-15 Ausonia Farma Srl Composizioni farmaceutiche ad attivita antibatterica contro infezioni da germi gram-positivi e gram-negativi.
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device

Also Published As

Publication number Publication date
IE843033L (en) 1985-06-01
IE57886B1 (en) 1993-05-05
HU192516B (en) 1987-06-29
DK158354C (da) 1990-10-01
AT390616B (de) 1990-06-11
IL73639A (en) 1988-06-30
SU1251807A3 (ru) 1986-08-15
ZM6384A1 (en) 1985-07-22
IN163078B (fr) 1988-08-06
FR2555990A1 (fr) 1985-06-07
YU199684A (en) 1987-02-28
US4600773A (en) 1986-07-15
YU45680B (sh) 1992-07-20
JO1347B1 (en) 1986-11-30
HUT35685A (en) 1985-07-29
KR870000527B1 (ko) 1987-03-14
CY1505A (en) 1990-08-03
IL73639A0 (en) 1985-02-28
MX159670A (es) 1989-08-02
IT1177329B (it) 1987-08-26
FI844631A0 (fi) 1984-11-26
SG59789G (en) 1989-12-29
DE3443065A1 (de) 1985-06-20
ES8602011A1 (es) 1985-11-01
GB8430073D0 (en) 1985-01-09
IT8423746A0 (it) 1984-11-27
CS248725B2 (en) 1987-02-12
MA20279A1 (fr) 1985-07-01
ZW19084A1 (en) 1985-06-12
FI80274C (fi) 1990-05-10
PT79553B (en) 1986-12-15
ZA849224B (en) 1986-07-30
EP0143658A2 (fr) 1985-06-05
NZ210357A (en) 1988-05-30
PT79553A (en) 1984-12-01
NO844711L (no) 1985-06-03
ATA373284A (de) 1989-11-15
LU85650A1 (fr) 1985-07-17
EP0143658A3 (en) 1986-02-12
BR8406037A (pt) 1985-08-27
FI844631L (fi) 1985-06-02
DK561284D0 (da) 1984-11-27
BG40966A3 (en) 1987-03-14
SE8405954L (sv) 1985-06-02
NL8403588A (nl) 1985-07-01
GB2150566B (en) 1987-08-26
EP0143658B1 (fr) 1989-03-22
DK158354B (da) 1990-05-07
SE8405954D0 (sv) 1984-11-26
PH20849A (en) 1987-05-08
GB2150566A (en) 1985-07-03
DD229410A5 (de) 1985-11-06
BE901142A (fr) 1985-05-28
AU566080B2 (en) 1987-10-08
OA07876A (fr) 1986-11-20
PL146014B1 (en) 1988-12-31
FR2555990B1 (fr) 1986-12-26
DE3443065C2 (fr) 1989-03-23
JPS60132990A (ja) 1985-07-16
PL250593A1 (en) 1985-07-30
KR850004765A (ko) 1985-07-27
MY102966A (en) 1993-03-31
AU3589784A (en) 1985-06-06
GT198400146A (es) 1986-05-20
JPH0548234B2 (fr) 1993-07-20
IT8423746A1 (it) 1986-05-27
SE464026B (sv) 1991-02-25
ES538019A0 (es) 1985-11-01
FI80274B (fi) 1990-01-31
GR81043B (en) 1985-03-27
DK561284A (da) 1985-06-02
CH661732A5 (de) 1987-08-14

Similar Documents

Publication Publication Date Title
KR100245938B1 (ko) 트리아졸릴티오메틸티오 세팔로스포린 염산염, 그의 결정성 수화물 및 이들의 제조방법
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
JPS62174018A (ja) 細菌性感染症治療剤
EP0143658B1 (fr) Dérivés de céphalosporines
KR20050002872A (ko) 9-데옥소-9ａ-아자-9ａ-메틸-9ａ-호모에리트로마이신 ａ의동종 구조의 유사 다형질체
JP2013184902A (ja) リファキシミン含有結晶
CA1234799A (fr) Derives de cephalosporine
US4607046A (en) 4-(1-imidazolylmethyl)cinnamic acid hydrochloride monohydrate and pharmaceutical compositions
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
MXPA01012325A (es) Formas polimorfas de un citrato cristalino de azobiciclo(2.2.2)octan-3-amina y sus composiciones farmaceuticas.
JPH08169890A (ja) セファロスポリン化合物の新規な結晶
GB2052483A (en) Crystalline cephalosporin salts
US4474780A (en) Crystalline cephalosporin
JP3012986B2 (ja) セフェム化合物及びその製造法
JP3242975B2 (ja) 消化管運動機能改善剤
JPH02134382A (ja) ビスベンジルイソキノリン誘導体
ZA200406971B (en) 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives.
MXPA97009873A (en) New crystaline form of acid 7 ([1alfa, 5alfa6alfa] -6-amino-3-azabiciclo [3.1.0] hex-3-il) -6-fluor-1- (2,4-difluorofenil) 1,4-dihydro -4-oxo-1,8-naftiridin-3-carboxilico anihdro, salt of acidomethane-sulfonico, compositions that contains it

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)